ARTICLE | Targets & Mechanisms
Poly drugs for polycomb
Novartis and Abbvie throw a third strike to Polycomb.
March 10, 2017 12:11 AM UTC
In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more competition for the HDAC antagonists dominating the field.
While HDAC inhibitors put epigenetic regulation on the map for cancer, the molecules have limitations that include hematologic toxicities...
BCIQ Company Profiles
BCIQ Target Profiles